Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 2Phase 1 1

Status

Completed 4Unknown 1Terminated 1

Sponsor Class

OTHER 2NIH 2INDUSTRY 2

Study Type

Interventional 6

Sponsor

Conditions

Leiomyoma 6Myofibroma 1Metrorrhagia 1Menorrhagia 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × ulipristal × Clear all
NCT00290251 2024-07-15

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
72 enrolled 7 charts

Leiomyoma

NCT04832906 2021-04-06

UA Versus UAE in Treatment of Fibroids

Ain Shams Maternity Hospital

Phase 4 Completed
70 enrolled

Leiomyoma, Metrorrhagia

NCT03342859 2021-01-06

Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

Bayer

Phase 1 Terminated
10 enrolled

Leiomyoma

NCT00044876 2019-12-17

Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
56 enrolled

Leiomyoma, Myofibroma

NCT02465814 2016-11-22

ASTEROID 2

Bayer

Phase 2 Completed
120 enrolled

Leiomyoma, Menorrhagia

NCT02288130 2016-11-03

MYOMEX

Amsterdam UMC, location VUmc

Phase 4 Unknown
100 enrolled

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡